Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States
Mepolizumab was associated with significant steroid-sparing benefits and significantly reduced rates of EGPA-related hospitalizations, EGPA relapses, and asthma exacerbations in this real-world study of US patients with EGPA, confirming the benefits of mepolizumab treatment seen in clinical trials.
Authors
- Ana Urosevic
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Sean D. MacKnight (ORCID: https://orcid.org/0000-0001-5032-2110)
- Sameer K. Mathur (ORCID: https://orcid.org/0000-0001-7656-0256)
- Arijita Deb (ORCID: https://orcid.org/0000-0002-4570-0364)
- Kaixin Zhang (ORCID: https://orcid.org/0009-0003-8194-8046)
- Jared Silver (ORCID: https://orcid.org/0000-0003-4392-0950)
- Cristina Martínez
Institutions
- University of Wisconsin–Madison (US)
- Group for Research in Decision Analysis (CA)
Publication Details
- Journal
- Annals of Allergy Asthma & Immunology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1016/j.anai.2024.11.004
- Citations
- 8
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 3.76